Crosslink has engineered a modular biologic domain which takes advantage of this difference to assemble therapeutics in tumors. Crosslink’s domain can be applied to virtually any therapeutic modality to improve tumor specific targeting and enhanced activity. We are currently focused on developing first-in-class/best-in-class applications in antibody drug conjugates and radioligand therapies.